BioSpace News Archive

Drug Development

Newron’s Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III

At the six-month follow-up, about 40% of patients treated with Newron Pharmaceuticals’ evenamide improved so much that they no longer meet the Phase II study’s original eligibility criteria.

October 10, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Xenon’s Add-On Epilepsy Treatment Shows Promising Phase IIb Efficacy, Safety

Patients treated with Xenon Pharmaceuticals’ investigational potassium channel opener XEN1101 experienced a significant and dose-dependent reduction in seizure frequency.

October 10, 2023
·
2 min read
·
Tristan Manalac
Deals

Biotech Bankruptcies Skyrocket

From Statera Biopharma and Sorrento Therapeutics to Aceragen and Infinity Pharmaceuticals, 2023 has seen a record high 28 bankruptcies in the biotech space so far. Here’s why.

October 10, 2023
·
6 min read
·
Ana Mulero
Drug Development

Akero’s Phase IIb NASH Data Disappoints, Sends Stock Plummeting

Both low and high doses of Akero Therapeutics’ lead candidate efruxifermin failed to significantly outperform placebo at improving liver fibrosis without worsening non-alcoholic steatohepatitis.

October 10, 2023
·
3 min read
·
Tristan Manalac
Drug Development

Opinion: Big Tech’s Move into Biopharma Could Disrupt the Industry

Google and Microsoft are already making inroads into drug development, but smaller biotechs focused on AI may end up leading the charge.

October 10, 2023
·
3 min read
·
Hanjo Kim
Drug Development

Merck Touts Keytruda Phase III NSCLC Survival Data Ahead of FDA Decision  

The pharma giant’s anti-PD-1 therapy met its dual primary endpoint of overall survival as a treatment regimen for non-small cell lung cancer patients, as the FDA’s Oct. 16 PDUFA date looms.  

October 10, 2023
·
2 min read
·
Kate Goodwin
Business

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Specific Biologics Inc. is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director.

October 10, 2023
·
6 min read
BioMidwest

Akita Biosciences Launches to Pioneer Novel Intranasal Therapies

Akita Biosciences, a biotechnology company focused on consumer health, is launching today with a mission to bring novel therapies to market.

October 10, 2023
·
3 min read
Business

Florida Cancer Specialists & Research Institute Announces Bradley Monk, MD as Medical Director of Late-Phase Clinical Research Program

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Bradley Monk, MD will join the statewide practice as Medical Director of Late-Phase Research, effective January 1, 2024.

October 10, 2023
·
5 min read
FDA clears Intelivation Technologies new Hammerdesis™ Interphalangeal Fusion System

Intelivation Technologies, an innovative medical device company with a cutting-edge orthopedic portfolio announced today that it has received clearance from the Food and Drug Administration for its Hammerdesis™ Interphalangeal Fusion System.

October 10, 2023
·
1 min read